- PBT-6, a Novel PI3KC2γ Inhibitor in Rheumatoid Arthritis
-
Kim J, Jung KH, Yoo J, Park JH, Yan HH, Fang Z, Lim JH, Kwon SR, Kim MK, Park HJ, Hong SS
- KMID: 2507836
- Biomol Ther.
- 2020 Mar;28(2):172-183.
- doi: 10.4062/biomolther.2019.153
Phosphoinositide 3-kinase (PI3K) is considered as a promising therapeutic target for rheumatoid arthritis (RA) because of its involvement in inflammatory processes. However, limited studies have reported the involvement of PI3KC2γ... -
- CITED
-
- Close
- SHARE
-
- Close
- Combination Therapy of the Active KRAS-Targeting Antibody inRas37 and a PI3K Inhibitor in Pancreatic Cancer
-
Lee JE, Woo MG, Jung KH, Kang YW, Shin SM, Son MK, Fang Z, Yan HH, Park JH, Yoon YC, Kim YS, Hong SS
- KMID: 2529893
- Biomol Ther.
- 2022 May;30(3):274-283.
- doi: 10.4062/biomolther.2021.145
KRAS activating mutations, which are present in more than 90% of pancreatic cancers, drive tumor dependency on the RAS/ mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K)/AKT signaling pathways. Therefore,... -
- CITED
-
- Close
- SHARE
-
- Close
